✦ LIBER ✦

A scenario-based integrated approach for modeling carbon price risk

✍ Scribed by Zhu, Zili ;Graham, Paul ;Reedman, Luke ;Lo, Thomas

Book ID: 106295853
Publisher: Springer
Year: 2009
Weight: 527 KB
Volume: 32
Category: Article
ISSN: 1127-1035
DOI: 10.1007/s10203-009-0086-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An approximate solution approach for a s

An approximate solution approach for a scenario-based capital budgeting model

✍ Anabela Costa; José M. P. Paixão 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 471 KB

A Rule-Based, Integrated Modelling Appro

A Rule-Based, Integrated Modelling Approach for Object-Oriented Systems

✍ Benjamin Braatz 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 220 KB

A fuzzy set-based approach for model-bas

A fuzzy set-based approach for model-based Internet-banking System security risk assessment

✍ Li Hetian; Liu Yun; He Dequan 📂 Article 📅 2006 🏛 Wuhan University 🌐 English ⚖ 330 KB

Multi-model integration in a decision su

Multi-model integration in a decision support system: a technical user interface approach for watershed and lake management scenarios

✍ David Lam; Luis Leon; Stuart Hamilton; Norm Crookshank; Derek Bonin; David Swayn 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 372 KB

A process-based conversion model for cae

A process-based conversion model for caesium-137 derived erosion rates on agricultural land: an integrated spatial approach

✍ K. Van Oost; G. Govers; W. Van Muysen 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

Utility of a physiologically–based pharm

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4